ReviewClinical diabetes and endocrinology2016
Lipoprotein (a), an independent cardiovascular risk marker.
Review in Clinical diabetes and endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Effects of High-Phenolic Extra Virgin Olive Oil (EVOO) on the Lipid Profile of Patients with Hyperlipidemia: A Randomized Clinical Trial.Nutrients · 2025Trial
- Interpreting the Evidence on Wine Consumption and Health: A Narrative Review of the J-Shaped Association and Contemporary Alcohol Guidelines.Nutrients · 2026Review
- Nicotinamide Adenine Dinucleotide Supplementation to Alleviate Heart Failure: A Mitochondrial Dysfunction Perspective.Nutrients · 2025Review
- Lipoprotein(a) and panvascular disease.Lipids in health and disease · 2025Review
- Lipoprotein apheresis affects the concentration of extracellular vesicles in patients with elevated lipoprotein (a).Scientific reports · 2024Article
- Impact of lipoprotein(a) and fibrinogen on prognosis in patients with coronary artery disease: A retrospective cohort study.Technology and health care : official journal of the European Society for Engineering and Medicine · 2024Article
- The Role of Biochemical Cardiac Markers in Atrial Fibrillation.The Journal of innovations in cardiac rhythm management · 2023Review
- Review of Isoflavones and Their Potential Clinical Impacts on Cardiovascular and Bone Metabolism Markers in Peritoneal Dialysis Patients.Preventive nutrition and food science · 2022Review
- Gene Expression Profiling of Markers of Inflammation, Angiogenesis, Coagulation and Fibrinolysis in Patients with Coronary Artery Disease with Very High Lipoprotein(a) Levels Treated with PCSK9 Inhibitors.Journal of cardiovascular development and disease · 2022Article
- Integrating machine learning with electronic health record data to facilitate detection of prolactin level and pharmacovigilance signals in olanzapine-treated patients.Frontiers in endocrinology · 2022Article
- How the love of muscle can break a heart: Impact of anabolic androgenic steroids on skeletal muscle hypertrophy, metabolic and cardiovascular health.Reviews in endocrine & metabolic disorders · 2021Review
- Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2021Review
- Identifying Genetic and Biological Determinants of Race-Ethnic Disparities in Stroke in the United States.Stroke · 2020Review
- Achieving low-density lipoprotein cholesterol targets as assessed by different methods in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH registry.Lipids in health and disease · 2020Article
- Racial Differences in Cardiovascular Biomarkers in the General Population.Journal of the American Heart Association · 2019Article
- Homocysteine and education but not lipoprotein (a) predict estimated 10-year risk of cardiovascular disease in blood donors: a community based cross-sectional study.BMC cardiovascular disorders · 2019Article
- Lipoprotein(a) and Risk of Ischemic Stroke in the REGARDS Study.Arteriosclerosis, thrombosis, and vascular biology · 2019Article
- PCSK9 in chronic kidney disease.International urology and nephrology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidemiological and genetic studies have identified elevated levels of lipoprotein (a) ((Lp(a)) as a causal and independent risk factor for cardiovascular diseases (CVD). The Lp(a)-induced increased risk of CVD may be mediated by both its proatherogenic and prothrombotic mechanisms. Several guidelines recommend screening of Lp(a) level; however, there are few treatment options for the management of patients with elevated Lp(a). Several new medications for Lp(a) are under development. PCSK9 inhibitors, apolipoprotein (a)-antisense, and apolipoprotein(B-100)-antisense mipomersen have shown promising results. Lp(a) reduction will continue to be an active area of investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.